DOCSLIB.ORG

Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers Amir A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers Amir A Cancer Therapy: Preclinical Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers Amir A. Jazaeri,1Christopher S. Awtrey,4 Gadisetti V.R. Chandramouli,1 Ya o E r i c Chu a n g, 2 Javed Khan,3 Christos Sotiriou,1Olga Aprelikova,1Cindy J. Yee,4 Kristin K. Zorn,6 Michael J. Birrer,6 J. Carl Barrett,1andJeff Boyd4,5 Abstract Purpose: The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma. Experimental Design: Gene expression profiles were generated from 21primary chemosensi- tive tumors and 24 primary chemoresistant tumors usingcDNA-based microarrays. Gene expres- sion profiles of both groups of primary tumors were then compared with those of 15 ovarian carcinomas obtained followingplatinum-based chemotherapy (‘‘postchemotherapy’’ tumors). A theme discovery tool was used to identify functional categories of genes involved in drug resistance. Results: Comparison of primary chemosensitive and chemoresistant tumors revealed differential expression of 85 genes (P < 0.001). Comparison of gene expression profiles of primary chemo- sensitive tumors and postchemotherapy tumors revealed more robust differences with 760 genes differentiatingthe two groups ( P < 0.001). In contrast, only 230 genes were differentially expressed between primary chemoresistant and postchemotherapy groups (P < 0.001). Common to both gene lists were 178 genes representing transcripts differentially expressed between post- chemotherapy tumors and all primary tumors irrespective of intrinsic chemosensitivity.The gene expression profile of postchemotherapy tumors compared with that of primary tumors revealed statistically significant overrepresentation of genes encoding extracellular matrix ^ related proteins. Conclusions: These data show that gene expression profiling can discriminate primary chemo- resistant from primary chemosensitive ovarian cancers. Gene expression profiles were also identi- fied that correlate with states of intrinsic and acquired chemoresistance and that represent targets for future investigation and potential therapeutic interventions. Platinum-based combination chemotherapy is the standard resistant to this treatment and subsequently show low response first-line treatment for advanced-stage epithelial ovarian carci- rates to other second-line agents (1–3). Early identification of noma. For the f75% of patients diagnosed with advanced- this group of patients could lead to their enrollment in clinical stage disease, 20% to 30% progress on or rapidly become trials or treatment with other experimental therapeutics because standard treatment affords them little benefit. Among initially chemosensitive patients, the vast majority will eventually relapse. Thus, chemoresistance may be present at the outset 1 2 Authors’Affiliations: Laboratory of Biosystems and Cancer and Radiation of treatment (intrinsic resistance) or may develop during Biology Branch, Center for Cancer Research, and 3Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland; 4Gynecology and Breast Research treatment (acquired resistance). In practice, ovarian cancers Laboratory, Department of Surgery, and 5Department of Medicine, Memorial are considered ‘‘platinum sensitive’’ if the clinical progression Sloan-KetteringCancer Center, New York,New York; and 6Department of Cell and free interval is >6 months, and evidence suggests that the longer Cancer Biology, Center for Cancer Research, National Cancer Institute, Rockville, this interval, the higher the subsequent response rates to Maryland Received 12/27/04; revised 5/31/05; accepted 6/16/05. additional chemotherapy (4–6). Grant support: NIH grant U01 CA88175 (J. Boyd) and Gynecologic Cancer Understanding the biological mechanisms underlying che- Foundation, National Cancer Institute Gynecologic Oncology Fellowship Program moresistance is of utmost importance for improving the (A.A. Jazaeri and K.K. Zorn). treatment and outcome of ovarian cancer. This topic has been The costs of publication of this article were defrayed in part by the payment of page the subject of intense research, and previous studies on charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. chemoresistance in ovarian cancer have investigated potential Note: Supplementary data for this article are available at Clinical Cancer Research involvement of molecules involved in drug transport, apopto- Online (http://clincancerres.aacrjournals.org/). sis, DNA repair, and detoxification pathways (7–11). Much of Requests for reprints: Jeff Boyd, Department of Surgery, Memorial Sloan- this research has been done using cell culture models and far KetteringCancer Center, Box 201, 1275 York Avenue, New York, NY 10021. Phone: 212-639-8608; Fax: 212-717-3538; E-mail: [email protected]. fewer data are available on the relevance of these studies to, and F 2005 American Association for Cancer Research. biomarkers and potential mechanisms of drug resistance for, doi:10.1158/1078-0432.CCR-04-2682 clinical samples. Clin Cancer Res 2005;11(17) September 1, 2005 6300 www.aacrjournals.org Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2005 American Association for Cancer Research. Molecular Profile of Drug Resistance in Ovarian Cancer The availability of new high-throughput screening techniques associated with both intrinsic and acquired chemoresistance in has allowed for more global investigations of molecular profiles ovarian cancer. The first aim of this investigation was to deter- associated with chemoresistance. In the present study, cDNA mine if intrinsically chemoresistant and chemosensitive tumors microarrays were used to investigate gene expression patterns could be distinguished based on their gene expression profiles. Ta b l e 1. Clinicopathologic features of primary ovarian cancer cases c Case no. Age* Histology Stage Grade Chemotherapy DFE Primary chemoresistant R1 49 Clear cell IIIC 3 Carboplatin/paclitaxel 0 R2 6 1 Endometrioid IIIC 3 Carboplatin/paclitaxel 0 R3 6 1 Serous IV 3 Carboplatin/paclitaxel 0 R4 49 Serous IIIC 2 Carboplatin/paclitaxel 0 R5 77 Serous IIIC NAb Carboplatin/paclitaxel 0 R6 49 Serous IIIC 2 Carboplatin/paclitaxel 0 R7 55 Serous IV 3 Carboplatin/paclitaxel 0 R8 56 Serous IIIC 2-3 Carboplatin/paclitaxel 0 R9 6 1 Serous IIIC 3 Carboplatin/paclitaxel 0 R10 73 Serous IV 3 Carboplatin/paclitaxel 0 R11 78 Serous IIIC 3 Carboplatin/paclitaxel 0 R12 7 1 Serous IV 2 Carboplatin/paclitaxel 0 R13 52 Serous IV 2 Carboplatin/paclitaxel 0 R14 64 Serous IIIA 1 Carboplatin/paclitaxel 0 R15 49 Serous IIIC 2 Carboplatin/paclitaxel 0 R16 47 Serous IV 3 Carboplatin/paclitaxel 0 R17 66 Serous IIIC 3 Cisplatin/cyclophosphamide 0 R18 69 Serous IV 2 Cisplatin/cyclophosphamide 0 R19 4 4 Serous IV 2 HD x cisplatin/cyclophosphamide 0 R20 35 Serous IV 2 Cisplatin/cyclophosphamide 0 R21 67 Serous IIIC 2-3 Cisplatin/cyclophosphamide 0 R22 63 Endometrioid IIIC 3 Carboplatin/paclitaxel 0 R23 76 Serous IIIC 3 Carboplatin 0 R24 65 Serous IIIC 2 Carboplatin/paclitaxel 0 Primary chemosensitive S1 5 1 Serous IV 2 Carboplatin/paclitaxel 35 S2 45 Endometrioid IIIC 2-3 HDCarboplatin/paclitaxel 41 S3 65 Mixed IIIC 3 Carboplatin/paclitaxel 13 S4 77 Serous IIIC 2-3 Carboplatin/paclitaxel 3 1 S5 53 Serous IIIC 3 Carboplatin/paclitaxel 32 S6 71 Serous IIIC 3 Carboplatin/paclitaxel 30 S7 55 Serous IIIC 3 Carboplatin/paclitaxel 19 S8 78 Endometrioid IIIC 2-3 Carboplatin/paclitaxel 24 S9 46 Endometrioid IIIC 3 Carboplatin/paclitaxel 2 1 S10 69 Serous IIIC 2 Carboplatin/paclitaxel 14 S11 54 Serous IV 1 Carboplatin/docetaxel 18 S12 53 Serous IIIC 2 Carboplatin/paclitaxel 18 S13 77 Serous IIIB 3 Carboplatin/paclitaxel 2 1 S14 56 Serous IIC 2 Carboplatin/paclitaxel 16 S15 44 Serous IIIC 2 Carboplatin/paclitaxel 16 S16 59 Carcinoma IIIC 3 Carboplatin/paclitaxel 16 S1744Serous IIICNACarboplatin/paclitaxel 13 S18 69 Serous IIIC 2 Carboplatin/paclitaxel 2 1 S19 70 Carcinoma IIIC 3 Carboplatin/paclitaxel 36 S20 74 Serous IIIC 2 Carboplatin/paclitaxel 2 1 S21 57 Serous IIIC 2 Carboplatin/paclitaxel 18 *Age at time of surgery. cDisease-free interval followingcompletion of chemotherapy (months). bNot available. xHigh-dose chemotherapy with bone marrow transplant. www.aacrjournals.org 6301 Clin Cancer Res 2005;11(17) September 1,2005 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2005 American Association for Cancer Research. Cancer Therapy: Preclinical Ta b l e 2 . Clinicopathologic features of postchemotherapy ovarian cancer cases Case no. Age* Histology Stage Grade Clinical hx Chemotherapy PC1 57 Serous IIIC 2 NC/IDc Carboplatin/paclitaxel  3 PC2 74 Serous IIIB 3 NC/ID Carboplatin/paclitaxel  3 PC3 59 Serous IIIC 3 NC/ID Carboplatin/paclitaxel  3 PC4 77 Serous IIIC 2 NC/ID Carboplatin/paclitaxel  6 PC5 73 Serous IIIC 2 NC/ID Carboplatin/paclitaxel  6 PC6 68 Undifferentiated IV 3 NC/ID Carboplatin/paclitaxel  6 PC7 22 Serous IIIC 1 NC/ID Carboplatin/paclitaxel  6 PC8 71 Serous IV 3 NC/ID Carboplatin/paclitaxel  6 PC9 71 Serous IIIC 3 NC/ID Carboplatin/paclitaxel  6 PC10 45 Endometrioid IIIC 2 PSLb HDx Carboplatin/paclitaxel PC11 56 Serous IIIC 3 PSL Carboplatin/paclitaxel  6 PC12 58 mixed IIIC 3 PSL Carboplatin/paclitaxel  6 PC13 66 Serous IIIC 3 PSL Carboplatin/paclitaxel  6 PC14 42 Serous IIIC 3 PSL Carboplatin/paclitaxel  6 PC15 28 Serous IIIC 2 PSL Carboplatin/paclitaxel  6 *Age
Load more

Recommended publications
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Supplemental Material Annexin A2-S100A10 Represents the Regulatory Component of Maxi-Cl Channel Dependent on Protein Tyrosine De
    Supplemental Material Annexin A2-S100A10 Represents the Regulatory Component of Maxi-Cl Channel Dependent on Protein Tyrosine Dephosphorylation and Intracellular Ca2+ Md. Rafiqul Islama Toshiaki Okadaa Petr G. Merzlyaka,b Abduqodir H. Toychieva,c Yuhko Ando-Akatsukad Ravshan Z. Sabirova,b Yasunobu Okadaa,e aDivision of Cell Signaling, National Institute for Physiological Sciences (NIPS), Okazaki, Japan, bInstitute of Biophysics and Biochemistry, National University of Uzbekistan, Tashkent, Uzbekistan, cDepartment of Biological Sciences, State University of New York College of Optometry, New York, NY, USA, dDepartment of Cell Physiology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan, eDepartment of Physiology, Kyoto Prefectural University of Medicine, Kyoto, Japan Supplementary Material Supplementary Fig. 1. Maxi-Cl currents in C127 cells were unaffected by siRNA- mediated silencing of three annexin family member genes, Anxa1, Anxa3 and Anxa11. Effects of knockdown mediated by Anxa1-specific siRNA (A), Anxa3-specific siRNA (B) and Anxa11-specific siRNA (C). Top panels: The effects on expression of ANXA mRNAs in C127 cells treated with non-targeting siRNA (cnt) or Anxa1/3/11-specific siRNA (si) detected by RT-PCR using Gapdh as a control. M: molecular size markers (100-bp ladder). These data represent triplicate experiments. Upper-middle panels: Representative time courses of Maxi-Cl current activation recorded at +25 mV after patch excision from C127 cells transfected with Anxa1/3/11-specific siRNA. Lower-middle panels: Voltage- dependent inactivation pattern of Maxi-Cl currents elicited by applying single voltage step pulses from 0 to 25 and 50 mV. Bottom panels: Summary of the effects of non-targeting siRNA (Control) and Anxa1/3/11-specific siRNA on the mean Maxi-Cl currents recorded at +25 mV.
    [Show full text]
  • Molecular Mechanisms Regulating Mammalian Forebrain Development
    Molecular Mechanisms Regulating Mammalian Forebrain Development By David Chun Cheong Tsui A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto © Copyright by David Chun Cheong Tsui (2013) Title: Molecular Mechanisms Regulating Mammalian Forebrain Development Name: David Chun Cheong Tsui Degree: Doctor of Philosophy, 2013 Department: Institute of Medical Sciences, University of Toronto ABSTRACT While the extrinsic factors regulating neurogenesis in the developing forebrain have been widely studied, the mechanisms downstream of the various signaling pathways are relatively ill-defined. In particular, we focused on proteins that have been implicated in cognitive dysfunction. Here, we ask what role two cell intrinsic factors play in the development of two different neurogenic compartments in the forebrain. In the first part of the thesis, the transcription factor FoxP2, which is mutated in individuals who have specific language deficits, was identified to regulate neurogenesis in the developing cortex, in part by regulating the transition from the radial precursors to the transit amplifying intermediate progenitors. Moreover, we found that ectopic expression of the human homologue of the protein promotes neurogenesis in the murine cortex, thereby acting as a gain-of-function isoform. In the second part of the thesis, the histone acetyltransferase CREB-binding protein (CBP) was identified as regulating the generation of neurons from medial ganglionic eminence precursors, similar to its role in the developing cortex. But CBP also plays a more substantial role in the expression of late interneuron markers, suggesting that it is continuously required for the various stages of neurogenesis at least in the ventral neurogenic niche.
    [Show full text]
  • Original Article EFEMP2 Is Upregulated in Gliomas and Promotes Glioma Cell Proliferation and Invasion
    Int J Clin Exp Pathol 2015;8(9):10385-10393 www.ijcep.com /ISSN:1936-2625/IJCEP0013127 Original Article EFEMP2 is upregulated in gliomas and promotes glioma cell proliferation and invasion Long Wang, Qianxue Chen, Zhibiao Chen, Daofeng Tian, Haitao Xu, Qiang Cai, Baohui Liu, Gang Deng Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China Received July 19, 2015; Accepted August 25, 2015; Epub September 1, 2015; Published September 15, 2015 Abstract: Gliomas are the most common and aggressive form of primary brain tumor. Although EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2), an extracellular matrix (ECM) glycoprotein, is regarded as a candidate oncogene, little is known about the association of EFEMP2 and gliomas. Here, the expression of EFEMP2 was significantly increased in glioma tissues (n=60) compared to non-tumorous brain tissues (n=25). Silencing of EFEMP2 expression through RNA interference in two glioma cell lines (U87 and U373) remarkably inhibited cell proliferation and G1/S transition. More importantly, EFEMP2 silencing significantly induced cell apoptosis via increasing the ratio of Bax and Bcl-2. Additionally, knockdown of EFEMP2 significantly inhibited the invasive ability of both glioma cells, which was associated with the downregulated expression of metalloproteinase-2 (MMP-2) and MMP-9. In conclusion, expression of EFEMP2 was associated with the oncogenic potential of gliomas and silenc- ing of its expression can suppress cancer cell growth and metastasis. Inhibition of EFEMP2 may be a therapeutic strategy for gliomas. Keywords: Apoptosis, EFEMP2, G1/S transition, gliomas, metalloproteinase Introduction ing-EGF-like domains and a unique fibulin C-terminal domain [5].
    [Show full text]
  • Colon Cancer Recurrence‑Associated Genes Revealed by WGCNA Co‑Expression Network Analysis
    MOLECULAR MEDICINE REPORTS 16: 6499-6505, 2017 Colon cancer recurrence‑associated genes revealed by WGCNA co‑expression network analysis XIAOFENG ZHAI1,2*, QINGFENG XUE3*, QUN LIU1,2, YUYU GUO1,2 and ZHE CHEN1,2 1Department of Integrative Oncology, Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University; 2Department of Integrative Oncology, Changhai Hospital, Shanghai 200433; 3Department of Anesthesiology, 264 Hospital of The People's Liberation Army, Taiyuan, Shanxi 030001, P.R. China Received March 31, 2016; Accepted March 20, 2017 DOI: 10.3892/mmr.2017.7412 Abstract. The present study aimed to identify the revealed that the function of cell adhesion, biological adhe- recurrence-associated genes in colon cancer, which may sion, extracellular matrix (ECM) organization, pathways of provide theoretical evidence for the development of novel ECM‑receptor interaction and focal adhesion were the signifi- methods to prevent tumor recurrence. Colon cancer and cantly changed terms in colon cancer. In conclusion, SERP2, matched normal samples microarray data (E-GEOD-39582) EFEMP2, FBN1, SPARC, and LINC0219 were revealed to be were downloaded from ArrayExpress. Genes with signifi- the recurrence-associated molecular and prognostic indicators cant variation were identified, followed by the screening of in colon cancer by WGCNA co‑expression network analysis. differentially expressed genes (DEGs). Subsequently, the co-expression network of DEGs was constructed using the Introduction weighted correlation network analysis (WGCNA) method, which was verified using the validation dataset. The signifi- Colon cancer is one of the most common malignant tumors, cant modules associated with recurrence in the network were with a high incident rate in the 40-50 age group.
    [Show full text]
  • EFEMP2 Suppresses the Invasion of Lung Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition (EMT) and Down-Regulating Mmps
    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH EFEMP2 Suppresses the Invasion of Lung Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition (EMT) and Down-Regulating MMPs This article was published in the following Dove Press journal: OncoTargets and Therapy Liang Song1,* Background: Epidermal growth factor-containing fibulin-like extracellular matrix protein 2 Xiang-Xin Li2,* (EFEMP2), also known as fibulin-4, MBP1 and UPH1, is an extracellular matrix protein Xiang-Yan Liu1 associated with a variety of tumors. The purpose of this study was to investigate the Zhou Wang1 prognostic value and the function of EFEMP2 in lung cancer. Yang Yu 1 Methods: The mRNA and protein expression of EFEMP2 in lung normal and cancer tissues, lung cancer cell lines (A549, H460, H1299 and H1650) and normal epithelial cell Mo Shi1 line BEAS-2B were evaluated by immunohistochemistry, RT-qPCR and Western blotting. Bin Jiang1 1 The Public databases (Oncomine and Kaplan-Meier plotter) were used to investigate the Xiao-Peng He prognostic value of EFEMP2 in lung cancer. RNA interference (RNAi) and overexpression 1Department of Thoracic Surgery, transfection were performed to detect the effects of EFEMP2 up- or down-regulation on lung fi Shandong Provincial Hospital Af liated to normal and cancer cell proliferation, invasion and metastasis in vitro and in vivo. Shandong University, Jinan, Shandong, People’s Republic of China; 2Department Results: EFEMP2 was lowly expressed in lung cancer tissues and cells, and its low of Hematology, Qilu Hospital of expression was associated with malignant phenotype and poor prognosis of lung cancer.
    [Show full text]
  • 1.1.4.1. Tumour Suppressor Genes
    To my Mother and Father Learn from yesterday, live for today, hope for tomorrow. The important thing is not to stop questioning. Albert Einstein Inhibition of Tumourigenicity of Small Cell Lung Cancer by Simultaneous Suppression of Id1 and Id3 Expression Danqing Chen ABSTRACT Inhibitor of DNA binding (Id) proteins are a group of transcription factors belonging to the basic helix-loop-helix (bHLH) family and play a wide range of roles in differentiation, proliferation and cell cycle progression. Id proteins act as negative dominant regulators of other bHLH factors by making dimers to these factors to prevent them from binding to E-box of DNA and, hence, to inhibit transcription of target genes. In this work, we first established SCLC cell line N417-derived sublines expressing reduced levels of Id1 and Id3 by transfection of a single vector constructed to co-express two shRNAs simultaneously. Then we investigated the effect of either singly or jointly suppressed Id1 or Id3 on tumourigenicity of SCLC cells in vitro and in vivo. The molecular mechanisms involved in the functional roles of Id1 and Id3 were also assessed. Id1-suppressed cells and Id1 and Id3 double knockdown cells produced significant reductions in proliferation rate by more than 1.4- and 3.9-fold respectively when compared with the control. Soft agar assay showed the number of colonies produced by Id1-suppressed cells and Id1 and Id3 double knockdown cells were reduced by more than 13.7- and 233-fold respectively compared with the control. The suppression effect was also observed in the invasion assay which showed that Id1-suppressed cells and Id1 and Id3 double knockdown cells produced more than 1.7- and 4.6- fold reduction respectively in relative invasiveness.
    [Show full text]
  • 7648.Full.Pdf
    The Journal of Neuroscience, October 15, 2000, 20(20):7648–7656 Evidence That Helix-Loop-Helix Proteins Collaborate with Retinoblastoma Tumor Suppressor Protein to Regulate Cortical Neurogenesis Jean G. Toma, Hiba El-Bizri, Fanie Barnabe´ -Heider, Raquel Aloyz, and Freda D. Miller Center for Neuronal Survival, Montreal Neurological Institute, Montreal, Canada H3A 2B4 The retinoblastoma tumor suppressor protein (pRb) family is phenotypes were rescued by coexpression of a constitutively essential for cortical progenitors to exit the cell cycle and survive. activated pRb mutant. In contrast, Id2 overexpression in post- In this report, we test the hypothesis that pRb collaborates with mitotic cortical neurons affected neither neuronal gene expres- basic helix-loop-helix (bHLH) transcription factors to regulate sion nor survival. Thus, pRb collaborates with HLHs to ensure the cortical neurogenesis, taking advantage of the naturally occur- coordinate induction of terminal mitosis and neuronal gene ex- ring dominant-inhibitory HLH protein Id2. Overexpression of Id2 pression as cortical progenitors become neurons. in cortical progenitors completely inhibited the induction of Key words: neurogenesis; Id2; pRb; bHLH transcription fac- neuron-specific genes and led to apoptosis, presumably as a tors; cortical development; neuronal gene expression; ␣-tubulin; consequence of conflicting differentiation signals. Both of these neural progenitor cells; neurofilaments; apoptosis During embryogenesis, cycling neural progenitor cells in the ven- In particular, in the PNS, bHLHs such as Mash-1 (Johnson et al., tricular zones of the CNS commit to a neuronal fate, and as a 1990) and the neurogenins (Ma et al., 1996; Sommer et al., 1996) consequence of that decision, coordinately undergo terminal mito- regulate the genesis of defined neuronal populations (Guillemot et sis and induce early, neuron-specific genes.
    [Show full text]
  • Wo 2007/120847 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 25 October 2007 (25.10.2007) WO 2007/120847 A2 (51) International Patent Classification: (74) Agent: BAKER, C , Hunter; Choate, Hall & Stewart, A61K 38/21 (2006.01) Two International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2007/009172 AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, (22) International Filing Date: 12 April 2007 (12.04.2007) FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, (25) Filing Language: English LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, (26) Publication Language: English RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 60/792,275 14 April 2006 (14.04.2006) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): MASS¬ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ACHUSETTS INSTITUTE OF TECHNOLOGY European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, [US/US]; Room NE25-230, 5 Cambridge Center, Kendall FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, Square, Cambridge, MA 02142 (US).
    [Show full text]
  • ISL1 Is an Essential Determinant of Structural and Functional Tonotopic Representation of Sound
    bioRxiv preprint doi: https://doi.org/10.1101/2021.09.03.458707; this version posted September 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 ISL1 is an essential determinant of structural and functional tonotopic representation of 2 sound 3 4 5 Authors: Iva Filovaa, 1, Kateryna Pysanenkob,1, Mitra Tavakolia, Simona Vochyanovaa, 6 Martina Dvorakovaa, Romana Bohuslavovaa, Ondrej Smolika, Sarka Benesovac, Lukas 7 Valihrachc, Ebenezer N. Yamoahd, Josef Sykab,2, Bernd Fritzsche,2, and Gabriela Pavlinkovaa,2,* 8 9 Affiliations: 10 aLaboratory of Molecular Pathogenetics, Institute of Biotechnology CAS, 25250 Vestec, 11 Czechia 12 bDepartment of Auditory Neuroscience, Institute of Experimental Medicine CAS, 142 20 13 Prague, Czechia 14 cLaboratory of Gene Expression, Institute of Biotechnology CAS, 25250 Vestec, Czechia 15 dDepartment of Physiology, School of Medicine, University of Nevada Reno, NV 89557, USA 16 eDepartment of Biology, Department of Otolaryngology, University of Iowa, Iowa City, IA 17 52242-1324, USA 18 1I.F. and K.P. contributed equally to this work. 19 2contributed to the conceptualization, evaluation, and writing of this report. 20 *to whom correspondence should be addressed. 21 Email: [email protected] 22 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.09.03.458707; this version posted September 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 23 Abstract 24 A cardinal feature of the auditory pathway is frequency selectivity, represented in the form of 25 a tonotopic map from the cochlea to the cortex.
    [Show full text]
  • GEP Analysis Validates High Risk MDS and Acute Myeloid Leukemia Post
    Guerenne et al. Journal of Hematology & Oncology (2016) 9:5 DOI 10.1186/s13045-016-0235-8 RESEARCH Open Access GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways Laura Guerenne1,2, Stéphanie Beurlet1,2, Mohamed Said3, Petra Gorombei1,2, Carole Le Pogam1,2, Fabien Guidez1,2, Pierre de la Grange4, Nader Omidvar5, Valérie Vanneaux6, Ken Mills7, Ghulam J Mufti3, Laure Sarda-Mantel8,9, Maria Elena Noguera10, Marika Pla1,2,11, Pierre Fenaux1,2,10, Rose Ann Padua1,2,10†, Christine Chomienne1,2,10† and Patricia Krief1,2* Abstract Background: In spite of the recent discovery of genetic mutations in most myelodysplasic (MDS) patients, the pathophysiology of these disorders still remains poorly understood, and only few in vivo models are available to help unravel the disease. Methods: We performed global specific gene expression profiling and functional pathway analysis in purified Sca1+ cells of two MDS transgenic mouse models that mimic human high-risk MDS (HR-MDS) and acute myeloid leukemia (AML) post MDS, with NRASD12 and BCL2 transgenes under the control of different promoters MRP8NRASD12/tethBCL-2 or MRP8[NRASD12/hBCL-2], respectively. Results: Analysis of dysregulated genes that were unique to the diseased HR-MDS and AML post MDS mice and not their founder mice pointed first to pathways that had previously been reported in MDS patients, including DNA replication/damage/repair, cell cycle, apoptosis, immune responses, and canonical Wnt pathways, further validating these models at the gene expression level. Interestingly, pathways not previously reported in MDS were discovered.
    [Show full text]
  • Large-Scale Assessment of the Gliomasphere Model System
    Neuro-OncologyNeuro-Oncology Advance Access published April 25, 2016 Neuro-Oncology 2016; 0, 1–12, doi:10.1093/neuonc/now045 Large-scale assessment of the gliomasphere model system Dan R. Laks, Thomas J. Crisman, Michelle Y. S. Shih, Jack Mottahedeh, Fuying Gao, Jantzen Sperry, Matthew C. Garrett, William H. Yong, Timothy F. Cloughesy, Linda M. Liau, Albert Lai, Giovanni Coppola, and Harley I. Kornblum Department of Biological Chemistry, University of California, Los Angeles, California (D.R.L.); Department of Psychiatry and Downloaded from Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, University of California, Los Angeles, California (T.J.C., M.Y.S.S., J.M., F.G., M.C.G., G.C., H.I.K.); Department of Pharmacology, University of California, Los Angeles, California (J.S.); Department of Pathology, University of California, Los Angeles, California (W.H.Y.); Department of Neurology, University of California, Los Angeles, California (T.F.C., A.L., G.C.); Department of Neurosurgery, University of California, Los Angeles, California (L.M.L.); Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, California (H.I.K.); The Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California (W.H.Y., T.F.C., L.M.L., A.L., H.I.K.) http://neuro-oncology.oxfordjournals.org/ Corresponding Authors: Harley I. Kornblum, MD, PhD, Room 379 Neuroscience Research Building, 635 Charles E. Young Dr. South, Los Angeles, CA 90095 ([email protected]); Giovanni Coppola, MD, 695 Charles E. Young Dr. South, Los Angeles CA 90095 ([email protected]).
    [Show full text]